TXG vs BRKR

For growth investors, 10x Genomics, Inc.

(TXG) is the stronger pick with 5. 2% revenue growth year-over-year, versus 2. 1% for Bruker Corporation (BRKR). Analysts rate Bruker Corporation (BRKR) a "Buy" — based on 32 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Bruker Corporation (BRKR) delivered a total return of -36.

6%, compared to -84. 3% for 10x Genomics, Inc. (TXG). Over 10 years, the gap is even starker: BRKR returned +67. 1% versus TXG's -57. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bruker Corporation (BRKR) is the lower-risk stock at 1.

59β versus 10x Genomics, Inc. 's 2. 32β — meaning TXG is approximately 46% more volatile than BRKR relative to the S&P 500. On balance sheet safety, 10x Genomics, Inc. (TXG) carries a lower debt/equity ratio of 20% versus 81% for Bruker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), 10x Genomics, Inc.

(TXG) is pulling ahead at 5. 2% versus 2. 1% for Bruker Corporation (BRKR). On earnings-per-share growth, the picture is similar: 10x Genomics, Inc. grew EPS 77. 0% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, BRKR leads at 10. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bruker Corporation (BRKR) is the more profitable company, earning -0.

3% net margin versus -6. 8% for 10x Genomics, Inc. — meaning it keeps -0. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRKR leads at 6. 9% versus -17. 2% for TXG. At the gross margin level — before operating expenses — TXG leads at 69. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for BRKR: 23.

2% to $52. 13.

In this comparison, BRKR (0.

4% yield) pays a dividend. TXG does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bruker Corporation (BRKR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

10x Genomics, Inc. (TXG) carries a higher beta of 2. 32 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BRKR: +67. 1%, TXG: -57. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.